The Global Molybdenum-99 and Technetium-99m Market was valued at USD 355 Million in 2023 and is projected to reach USD 546.02 Million by 2032, growing at a Compound Annual Growth Rate (CAGR) of 4.9% during the forecast period (2024–2032). This growth is being driven by the rising global prevalence of cancer and cardiovascular diseases, aging populations requiring precise diagnostics, and the critical need for a secure, diversified supply of medical isotopes to prevent global shortages.

As the nuclear medicine sector advances toward enhanced diagnostic accuracy and supply chain resilience, the spotlight is on the key producers and innovators who are ensuring the reliable delivery of these life-saving isotopes. In this blog, we profile the Top 10 Companies in the Molybdenum-99 and Technetium-99m Industry—a mix of reactor operators, specialized processors, and strategic distributors essential to modern healthcare diagnostics.

---

🔟 1. Curium

Headquarters: Paris, France
Key Offering: Technetium-99m Generators, Finished Dose Radiopharmaceuticals

Curium is a global leader in nuclear medicine, formed from the union of Mallinckrodt Nuclear Medicine and IBA Molecular. It is a powerhouse in the supply chain for Tc-99m, producing millions of patient doses annually and operating a vast network of radiopharmacies and generator distribution centers worldwide.

Strategic Initiatives:

• Global logistics network for reliable generator delivery
• Investment in next-generation non-HEU (Low Enriched Uranium) Mo-99 supply
• Focus on end-to-end solutions from isotope to final patient dose

Download FREE Sample Report:
Molybdenum-99 and Technetium-99m Market – View in Detailed Research Report

---

9️⃣ 2. NorthStar Medical Radioisotopes, LLC

Headquarters: Beloit, Wisconsin, USA
Key Offering: Non-HEU Molybdenum-99, RadioGenix® System (Tc-99m)

NorthStar is a pioneer in non-uranium-based Mo-99 production in the United States. Its innovative technology uses electron accelerators to irradiate Mo-100 targets, eliminating the need for highly enriched uranium (HEU) and enhancing U.S. supply security.

Strategic Initiatives:

• Leading the transition to non-HEU Mo-99 in North America
• Commercial-scale production at its Wisconsin facility
• Strategic partnerships for global distribution of its RadioGenix® system

---

8️⃣ 3. ANSTO (Australian Nuclear Science and Technology Organisation)

Headquarters: Lucas Heights, New South Wales, Australia
Key Offering: ANSTO Mo-99, Technetium-99m Generators

ANSTO operates Australia’s OPAL multipurpose reactor, a major global supplier of Mo-99. It produces enough isotopes to meet approximately one-third of the world’s demand outside the U.S. and Europe, playing a vital role in creating supply diversity and geographic resilience.

Strategic Initiatives:

• Production of LEU-based Mo-99 to support non-proliferation goals
• Expansion of nuclear medicine manufacturing capacity
• Supply agreements across the Asia-Pacific region and beyond

---

7️⃣ 4. NRG (Nuclear Research and Consultancy Group) / PALLAS

Headquarters: Petten, The Netherlands
Key Offering: Molybdenum-99 from the High Flux Reactor (HFR)

NRG operates the High Flux Reactor in Petten, a historic and crucial facility for global Mo-99 production. The company is central to the European supply chain, with its isotopes processed by partners like Curium. The transition to the new PALLAS reactor aims to secure long-term European production.

Strategic Initiatives:

• Coordinating the PALLAS reactor project for future Mo-99 production
• Maintaining reliable HEU-based supply during the reactor transition
• Contributing to EU strategic autonomy in medical isotopes

---

6️⃣ 5. IRE (Institut national des RadioÉléments)

Headquarters: Fleurus, Belgium
Key Offering: Molybdenum-99, Lutetium-177, other medical radioisotopes

IRE is a key European player in radioisotope production, irradiating targets at partner reactors (like BR2 in Belgium) and processing them at its Fleurus facility. It is a major supplier of Mo-99 to generator manufacturers globally and is investing in diversified production methods.

Strategic Initiatives:

• Investments in alternative production technologies (cyclotron-based)
• Expanding portfolio beyond Mo-99/Tc-99m to therapeutic isotopes
• Ensuring compliance with evolving EU regulations on isotope supply

Download FREE Sample Report:
Molybdenum-99 and Technetium-99m Market – View in Detailed Research Report

---

5️⃣ 6. NTP Radioisotopes (SOC) Ltd.

Headquarters: Pelindaba, South Africa
Key Offering: Molybdenum-99, Technetium-99m Generators

NTP, a subsidiary of the South African Nuclear Energy Corporation (Necsa), operates the SAFARI-1 research reactor. It is a leading global supplier of Mo-99, renowned for its reliable production using LEU targets, which aligns with global non-proliferation efforts.

Strategic Initiatives:

• Long-standing commitment to 100% LEU-based Mo-99 production
• Key supplier to emerging markets and established partners worldwide
• Continuous reactor optimization to maximize output and reliability

---

4️⃣ 7. Rosatom (JSC Rusatom Healthcare)

Headquarters: Moscow, Russia
Key Offering: Molybdenum-99, Technetium-99m Generators, Nuclear Medicine Equipment

Through its subsidiary Rusatom Healthcare, the Russian state nuclear corporation Rosatom is a significant producer of Mo-99, primarily from the Research Institute of Atomic Reactors (RIAR). It serves a large domestic market and exports isotopes to countries in the CIS, Asia, and beyond.

Strategic Initiatives:

• Developing new radioisotope production facilities
• Expanding its international footprint in nuclear medicine
• Integrating the supply chain from reactor to generator distribution

---

3️⃣ 8. BWXT Medical Ltd.

Headquarters: Ottawa, Ontario, Canada
Key Offering: Technetium-99m Generators, Medical Isotope Processing

BWXT Medical is a critical processor and generator manufacturer. It historically processed Mo-99 from the NRU reactor and continues to be a vital converter of raw isotope into usable Tc-99m generators for the North American and global markets, partnering with producers like ANSTO.

Strategic Initiatives:

• Securing multi-source supply agreements with global producers
• Maintaining cGMP-compliant processing facilities
• Ensuring seamless generator logistics for hospital networks

---

2️⃣ 9. Eckert & Ziegler

Headquarters: Berlin, Germany
Key Offering: Isotope Technology, Radiopharmaceutical Components, Tc-99m Generator Systems

Eckert & Ziegler is a specialist in isotope technology and radiopharmaceutical components. While not a primary reactor-based producer, it is a crucial enabler in the value chain, providing the technology, components, and services essential for distributing and utilizing Tc-99m generators globally.

Strategic Initiatives:

• Providing key components for generator manufacturing
• Investment in logistics and service solutions for nuclear medicine
• Focus on the entire ecosystem beyond raw isotope production

---

1️⃣ 10. China National Nuclear Corporation (CNNC) / CGN

Headquarters: Beijing, China
Key Offering: Molybdenum-99, Domestic Tc-99m Generator Supply

China’s major nuclear entities, CNNC and China General Nuclear (CGN), are rapidly scaling up domestic production of medical isotopes to meet the country’s enormous and growing healthcare demands. Several research reactors are dedicated to Mo-99 production, aiming for self-sufficiency.

Strategic Initiatives:

• Aggressive expansion of domestic Mo-99/Tc-99m production capacity
• Development of a fully integrated domestic supply chain
• Potential future role as a significant exporter to the Asia-Pacific region

Read Full Report:
Molybdenum-99 and Technetium-99m Market – View in Detailed Research Report

---

🌍 Outlook: The Future of Diagnostic Isotopes Is Secure and Innovative

The Molybdenum-99 and Technetium-99m market is undergoing a fundamental transformation. While traditional reactor-based production still dominates, the industry is investing heavily in supply chain diversification, non-HEU technologies, and next-generation production methods to mitigate the risks of reactor outages and geopolitical fragility.

📈 Key Trends Shaping the Market:

• Accelerated shift from HEU to LEU and non-uranium-based Mo-99 production
• Government-backed initiatives for national and regional supply security
• Growth in point-of-care generator systems like NorthStar’s RadioGenix®
• Integration of diagnostic Tc-99m with emerging therapeutic radiopharmaceuticals

Read Full Report:
Molybdenum-99 and Technetium-99m Market – View in Detailed Research Report

The companies listed above are not only powering millions of critical medical diagnoses each year—they are spearheading the technological and supply chain evolution that will ensure this essential pillar of modern medicine remains robust for decades to come.